London, UK, 6 September 2023: PharmaVentures is pleased to announce that it acted as the exclusive advisor to Douglas Pharmaceuticals on its U.S. license agreement with Daré Bioscience, Inc. (NASDAQ: DARE) to develop and commercialise R-131-2, a novel topical medicinal candidate for the treatment for cervical intraepithelial neoplasia.

Under the agreement with Douglas Pharmaceuticals, Daré Bioscience will be responsible for advancing the development of R-131-2 in the U.S. while Douglas Pharmaceuticals will retain rights in other territories. Douglas Pharmaceuticals will also support the further development of the product and regulatory package and manufacture the drug for clinical and commercial supply.

Stephen Waterman, Managing Director at PharmaVentures, said “We are pleased to have assisted Douglas in finding a suitable U.S. partner for the development and commercialisation of R-131-2 and excited for the potential impact this pharmacological treatment can have on women affected with these conditions. We look forward to helping Douglas with more partnerships for R-131-2.”

Fintan Walton, Founder and CEO of PharmaVentures, said “PharmaVentures has advised and supported our long-standing client, Douglas Pharmaceuticals, through the discussion with Daré Bioscience. This is yet another exciting example of how PharmaVentures can help clients reach their partnering goals.”

– Ends –


For further information, please contact:

Stephen Waterman
Managing Director


About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances.

For over 30 years, PharmaVentures has acted as advisor on over 1000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning.

PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

  •  M&A (divestments, mergers, acquisitions, and strategic transactions)
  • Licensing (in and out licensing)
  • Fundraising Support
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Valuations (licensing, M&A, and fundraising)
  • Pricing and Market Access

PharmaVentures is based in London, UK, and employs over 30 professionals and has associates in Europe and Asia-Pacific.

NOTE: This Press release is issued by PharmaVentures Limited, whose wholly owned subsidiary PharmaVentures Capital Limited is authorised and regulated by the Financial Conduct Authority (741356). This communication is for information purposes only and does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.

For more details, visit

Follow us on LinkedIn:

About Douglas Pharmaceuticals

Douglas Pharmaceuticals is New Zealand’s largest privately owned pharmaceutical and healthcare company. It was founded in 1967 by pharmacist Sir Graeme Douglas and today employs over 700 people and exports to over 40 countries around the world.

The Douglas mission is to ‘Improve Lives’ by providing innovative, competitive, and high-quality healthcare solutions. Douglas’ core business is producing prescription drugs for areas including oncology, dermatology, the central nervous system, and immunology. Douglas develops, manufactures, and distributes novel and generic products, with a preference for those where there is a strong intellectual property position as well as technical complexity in areas of high unmet need.

Furthermore, as of Sep 2022 a state-of-the-art research and development facility has opened in West Auckland, which aims to use world class medical research to find solutions for a range of serious illnesses. The $50MM Douglas Innovation centre is part of the long-established Douglas campus in Auckland. The three story, 4,500sq metre building was 18 months in construction. It employs 100 people and includes laboratory, pilot scale product development suites, commercial manufacturing rooms which can handle highly potent and cytotoxic products, and office space. Manufacturing capabilities include soft gelatine encapsulation, liquids, creams, and modified release oral dosage forms.

For more information, please visit: